|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...9293949596979899100101102...156157» |
- Trial primary completion date: SisSLE: Autoimmunity in Sisters of Lupus Patients (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=800, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Dec 2013 --> Dec 2016
- Trial primary completion date: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=123, Completed, Sponsor: University of Washington
Trial primary completion date: Dec 2013 --> Dec 2016 Trial primary completion date: Sep 2014 --> Dec 2012
- Trial primary completion date: NARAC: Genetic Registry for Rheumatoid Arthritis (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=3000, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Sep 2014 --> Dec 2012 Trial primary completion date: Dec 2013 --> Dec 2015
- Enrollment open: Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=10, Recruiting, Sponsor: University of Manitoba
Trial primary completion date: Dec 2013 --> Dec 2015 Not yet recruiting --> Recruiting
- Enrollment closed: Reducing Depressive Symptoms in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Cosentyx (secukinumab) / Novartis
Biomarker, Trial completion: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jun 12, 2014
P2, N=500, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: inMotion: Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=123, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial primary completion date: DILT1D: Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2 (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=40, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> May 2014
- ||||| I.V.-Globulin SN (human immune globulin intravenous) / Green Cross
Trial initiation date: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia (clinicaltrials.gov) - Jun 12, 2014
P3, N=70, Recruiting, Sponsor: Green Cross Corporation
Trial primary completion date: Jan 2015 --> May 2014 Initiation date: Mar 2014 --> Jun 2014
- |||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Enrollment open: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Jun 12, 2014
P2, N=330, Recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- |||||| I.V.-Globulin SN (human immune globulin intravenous) / Green Cross
Enrollment open: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia (clinicaltrials.gov) - Jun 12, 2014
P3, N=70, Recruiting, Sponsor: Green Cross Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: PST Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=20, Completed, Sponsor: Chang Gung Memorial Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: DILT1D: Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2 (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=40, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Recruiting --> Completed Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 8, 2014
P=N/A, N=132, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed N=305 --> 132
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 8, 2014
P=N/A, N=132, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=305 --> 132 Active, not recruiting --> Completed
- | Cytovene (ganciclovir) / Roche, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Islet Transplantation for Type 1 Diabetes (clinicaltrials.gov) - Jun 8, 2014
P2, N=36, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Biomarker, Trial primary completion date: BATTER-UP: Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=301, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Trial primary completion date: Apr 2013 --> Jul 2013
- ||| Biomarker, Trial completion: BATTER-UP: Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=301, Completed, Sponsor: Biogen Idec
Trial primary completion date: Apr 2013 --> Jul 2013 Active, not recruiting --> Completed
- Enrollment open: Full Day and Night Closed-Loop With DiAs Platform (clinicaltrials.gov) - Jun 5, 2014
P=N/A, N=48, Recruiting, Sponsor: University of Virginia
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Lantus (insulin glargine) / Sanofi
Trial completion: EDITION JP I: Comparison of a New Formulation of Insulin Glargine With Lantus (clinicaltrials.gov) - Jun 5, 2014
P3, N=243, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Enrollment closed: Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=260000, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Clinical: Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=40, Recruiting, Sponsor: Vastra Gotaland Region
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: NURTURE 1: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor ? (Anti-TNF?) Agents (CAIN457F2309 and CAIN457F2309E1) (clinicaltrials.gov) - Jun 4, 2014
P3, N=550, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Ilaris (canakinumab) / Novartis
Trial primary completion date: ?-SPECIFIC 3: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-na (clinicaltrials.gov) - Jun 4, 2014
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Nov 2014
- Clinical: A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=9, Enrolling by invitation, Sponsor: University of Aarhus
- ||| Enrollment closed: Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) - Jun 3, 2014
P4, N=151, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 3, 2014
P3, N=162, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Active, not recruiting --> Completed Trial primary completion date: Feb 2014 --> Sep 2014
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Trial primary completion date: Feb 2014 --> Sep 2014 N=18 --> 48
- || rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P3 trial: TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) - Jun 3, 2014
P3, N=536, Not yet recruiting, Sponsor: University of Padova
- | Trial initiation date, HEOR: A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 (clinicaltrials.gov) - Jun 3, 2014
P4, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
N=18 --> 48 Initiation date: Jul 2012 --> Oct 2012
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) - Jun 2, 2014
P4, N=90, Recruiting, Sponsor: EMD Serono
Initiation date: Jul 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- Trial primary completion date: Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=18, Completed, Sponsor: SetPoint Medical Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Mar 2014
- Clinical: Tight Control of Disease Activity Among Patients With RA Based on a Systematic Telemedicine Treatment Strategy (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=300, Recruiting, Sponsor: University of Aarhus
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Enrollment closed: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P3, N=526, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- | Trial completion: Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=18, Completed, Sponsor: SetPoint Medical Corporation
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: NURTURE 1: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor ? (Anti-TNF?) Agents (CAIN457F2309 and CAIN457F2309E1) (clinicaltrials.gov) - Jun 2, 2014
P3, N=548, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Aug 2015 --> Feb 2015
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases (clinicaltrials.gov) - Jun 2, 2014
P1, N=20, Recruiting, Sponsor: Duke University
Trial primary completion date: Aug 2015 --> Feb 2015 Trial primary completion date: Jan 2015 --> Jan 2018
- remtolumab (ABT-122) / AbbVie
Enrollment change: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P1, N=19, Completed, Sponsor: AbbVie
Trial primary completion date: Jan 2015 --> Jan 2018 N=24 --> 19
- Lumigan (bimatoprost) / Senju, AbbVie
New P3 trial: Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues (clinicaltrials.gov) - Jun 2, 2014
P3, N=20, Not yet recruiting, Sponsor: Rabin Medical Center
- teriflunomide / Generic mfg.
Enrollment open: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jun 2, 2014
P1, N=12, Recruiting, Sponsor: Sanofi
N=24 --> 19 Not yet recruiting --> Recruiting
- avdoralimab (IPH5401) / Innate
Enrollment closed, PK/PD data: A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P1, N=26, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | remtolumab (ABT-122) / AbbVie
Trial completion: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P1, N=19, Completed, Sponsor: AbbVie
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / AbbVie
Trial completion: Special Investigation of Humira (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=553, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=12, Not yet recruiting, Sponsor: University of Cambridge
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Nov 2014
- |||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jun 1, 2014
P3, N=60, Recruiting, Sponsor: Amgen
Trial primary completion date: May 2014 --> Nov 2014 Trial primary completion date: Apr 2015 --> Oct 2015
- Trial initiation date: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=12, Not yet recruiting, Sponsor: University of Cambridge
Trial primary completion date: Apr 2015 --> Oct 2015 Initiation date: Oct 2013 --> Jun 2014
- | paquinimod (ABR-215757) / Active Biotech
Biomarker, Enrollment change: Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jun 1, 2014
P2, N=13, Completed, Sponsor: Active Biotech AB
Initiation date: Oct 2013 --> Jun 2014 N=20 --> 13
- |||| remtolumab (ABT-122) / AbbVie
Enrollment open, P2 data: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jun 1, 2014
P2, N=160, Recruiting, Sponsor: AbbVie
N=20 --> 13 Not yet recruiting --> Recruiting
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNF? Agents (clinicaltrials.gov) - Jun 1, 2014
P3, N=630, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Mar 2017